Fabrice Lucien, PhD

🇫🇷🇨🇦🇺🇸 Associate Professor of Urology & Immunology - Mayo Clinic - Basic and Translational Research - Liquid biopsies and next-gen cancer immunotherapies

[Haidong Dong @hd_DongMDPhD]

Our newly published theoretical mathematical model of T-cell responses to PD-1 therapy, developed from more than a decade of clinical observations, offers new insights into the mechanisms and dynamics underlying cancer immunotherapy. | Science Advances https://t.co/zP5my1jlcR

[Amar Kishan @AmarUKishan]

Updated LUNAR analysis out in @EUplatinum. Now with a median follow-up of 32 months, exploratory analyses confirm the addition of 177Lu-PNT2002 to SBRT improves polymetastatic PFS (6 or more new lesion), castrate disease-free survival, and CT-based PFS (i.e., conventional MFS) https://t.co/qOiwvSSpbs

[Haidong Dong @hd_DongMDPhD]

After 15 years of our discovery of soluble PD-L1(B7-H1), we finally have a proof of it as a therapeutic target and have a way to specifically remove it in vivo to restore antitumor immunity. https://t.co/1VY6ENOVap

[Fabrice Lucien, PhD @flscientist]

Looking forward to sharing our progress on EV-based liquid biopsy and learning more on how to integrate computational biology in our work @iscb Great Plains.

[Fabrice Lucien, PhD @flscientist]

Tunneling NanoTubes (TNT) as an effective means for intercellular mRNA transfer in neighboring cells. Much more efficient than EV-mediated transfer.

https://t.co/hurnx4VV8b

[Fabrice Lucien, PhD @flscientist]

@HBorgesdaSilva @MayoClinic @TGenResearch Congratulations Henrique and wish you all the best for this new chapter

[Fabrice Lucien, PhD @flscientist]

@AnaSalazarPuer1 for sharing the blog post ;)

[Fabrice Lucien, PhD @flscientist]

ALWAYS validate your reagents with proper controls and don’t trust product sheets or prior publications.

When you see how much cost antibodies nowadays ($500+/100 micrograms), that’s shocking but unfortunately not surprising.

https://t.co/eeg2GOExXE

https://t.co/DHQaVaCbLC

[Fabrice Lucien, PhD @flscientist]

@aadel_chaudhuri The hill in Oxbow Park gives a good sweat. Good job 💪

[Fabrice Lucien, PhD @flscientist]

@CalaisJeremie @TubaKendi @UCLA @GustaveRoussy @UnivParisSaclay Bon retour à la maison et je te souhaite du succès dans ce nouveau chapitre personnel et professionnel. En espérant avoir la chance de se recroiser en meeting et peut être collaborer.

[Katy Beckermann @katy_beckermann]

Closing the night on prostate. From high risk localized disease discussion of best treatment options surgery vs radiation... To the mHSPC question that keeps coming up: who do you intensify, and who can you spare? Biomarkers are starting to answer it. 🎯

#GURounds expertly led by @KSchaffer17 with input from the entire Nashville team @BGarmezy @alantanmd @TomJayram @AKRadDoc @DavidMorrismd

Representation from @VUMCRadOnc @TNOncology @theGHCR @SarahCannonDocs

[Fabrice Lucien, PhD @flscientist]

@DrYukselUrun @chadinabhan @grok @OpenAI @claudeai @GeminiApp @DrChoueiri @ZiadBakouny @LeonidasPlatan1 @drenriquegrande @Martin_AngelMD @KidneyCancer @Dr_AmerZeidan @AminNassarMD @scserendipity1 And referee decision making

[Yalda Nikanpour @YaldaNikanpour]

Our new paper is out! 🎉

In mCRPC treated with PSMA-RLT, metastatic disease volume emerged as a key driver of outcomes.

A simple stratification that could sharpen how we select patients.

Full study 🔗
https://t.co/YppCotkEsS

@JackAndrewsMD @MayoRadiology @MayoUrology

[Fabrice Lucien, PhD @flscientist]

@DrAndrewLoblaw @GiulioFrancoli1 @dicataldovanes1 @BarbaraJereczek @Ric_Campi @ChadTangMD @TheLancetOncol @ESTRO_RT @CDNCancerTrials @niazi_Dr7 @DrPatCheung https://t.co/4TWhYKnovQ

[Fabrice Lucien, PhD @flscientist]

@piet_ost @GiuliaMarvaso84 @GiulioFrancoli1 @alongi_filippo @NicosiaMd @ChadTangMD We should integrate imaging and fluid markers. Let’s consider #extracellularvesicles as we showed their prognostic value in multiple cohorts. https://t.co/Kr4X4U4SZy
More to come @GiuliaMarvaso84

[Gianrico Farrugia @GFarrugiaMD]

I’m pleased to share Mayo Clinic has announced a strategic collaboration with @Microsoft to develop and deploy a frontier AI model designed specifically for healthcare. Read more: https://t.co/I6RGCtR8MF

[Zach Klaassen @zklaassen_md]

Brilliant discussant slide from @CalaisJeremie putting into context the results from AcTION and CONV01-alpha with PSMAddition and VISION

@urotoday #ASCO26

[Fabrice Lucien, PhD @flscientist]

@bashier_roya @AJangMD @MayoCancerCare @MayoUrology Yes we do :)

[Fabrice Lucien, PhD @flscientist]

Exciting work on EV-based biomarkers in advanced prostate cancer treated with Lu-177 PSMA, spearheaded by @AJangMD @MayoCancerCare @MayoUrology

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#5068 @ASCO #ASCO26 by @AJangMD👉 https://t.co/9FpEfmhiIJ👉Plasma-derived extracellular vesicles (EVs) in 123 pts w/ mPC treated w/ Lu-177 #prostatecancer➡️CEACAM5 + TROP2 EV composite best predicted PSA50 response (OR 2.96)👇 @flscientist @oncoalert @urotoday @PCF_science

[Mayo Clinic Urology @MayoUrology]

Mayo Clinic Urology was honored to host visiting professor Dr. Hashim Ahmed for a discussion on advances in prostate cancer screening, precision diagnosis, and focal therapy.
#ProstateCancer #FocalTherapy @imperialcollege @LondonProstate1 @SBoorjian @DerekLomas